FORM 4

Instruction 1(b).

(Print or Type Responses)

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average	a hurden				

hours per response...

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(1 mit of Type R	csponses)															
1. Name and Address of Reporting Person* Hochman David P			O	2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]					_x_	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner						
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE			\mathbf{S}	3. Date of Earliest Transaction (Month/Day/Year) 05/22/2019							Officer (give	title below)	Other	(specify below)		
NORWOOD, MA 02062			4	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group FilingCheck Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	<u>* </u>	(State)	(Zip)	Table I - Non-Derivative Securities Acqu					Acquired, I	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution I any (Month/Day		ate, if Co	(Instr. 8)		4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		(D) Owned Followin Transaction(s)		ecurities Beneficially ng Reported		wnership orm:	Beneficial	
						Code	V	Amoun	(A) or (D)	Price (Instr.	(Instr. 3 and 4)		o: (I	Indirect (Ownership Instr. 4)	
								in this a curre	form a ntly value	are not rec alid OMB	quired to re control nui	spond u mber.		on contained form displays		474 (9-02)
1. Title of Derivative Security (Instr. 3)		Conversion Date Execution Date (Month/Day/Year) any (Month/Day/Year)		4. 5. N c, if Transaction of D Code Secu (Instr. 8) Acq or D of (I (Inst		5. Num of Deriv Securiti Acquire or Disp of (D)	Number Derivative Curities equired (A) Disposed (D) astr. 3, 4,		piration Date		7. Title and of Underlying Securities	7. Title and Amount of Underlying		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownershi Form of Derivative Security: Direct (D or Indirec	Beneficial Ownership (Instr. 4)
				Cod	e V		(D)	Date Exercisal		epiration ate	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option(right to buy)	\$ 7.31	05/22/2019		A		33,300)	(1)	05	5/22/2029	Common Stock	33,300	\$ 0	33,300	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Hochman David P C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	X						

Signatures

/s/ David Hochman	06/28/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not re-	equired to respond unless the form displays a currently valid OMB number.